Table 3

Group data for serum bile acid composition

Percentage of total
serum bile acids (%) 		Non-acromegalic control subjects (n=6) Acromegalic patients
Not treated with OT (n=6) 		Treated with LTOT (n=8) Patients with simple constipation (n=8)
Placebo Cisapride Placebo Cisapride Placebo Cisapride Placebo Cisapride
CA53 (8.9)61 (8.9)34 (4.7)50 (6.5)47 (4.3)56 (4.9)29 (6.9)38 (8.1)
DCA16 (1.3)8.8 (2.2)3-b 24 (4.1)17 (3.0)3-b 22 (2.6)11 (3.5)3-b 40 (3.4)22 (3.4)3-a
CDCA30 (7.9)27 (7.4)38 (7.6)30 (5.9)28 (3.3)32 (5.7)28 (5.1)36 (7.4)
UDCA 2.4 (0.7) 2.7 (0.6) 3.5 (1.0) 2.6 (0.7) 2.8 (1.3) 1.6 (0.7) 2.8 (0.6) 3.6 (0.8)

  • Results are mean (SEM).

  • Unless otherwise indicated, differences between means were not statistically significant:

  • ↵3-a p<0.001,

  • ↵3-b p<0.01 versus placebo.

  • OT, octreotide; LTOT, long term octreotide; CA, cholic acid; DCA, deoxycholic acid; CDCA, chenodeoxycholic acid; UDCA, ursodeoxycholic acid.